XML 52 R34.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Data (Tables)

12 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Areas

Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.

(Millions of dollars)			2024																		2023																		2022
			United States						International						Total						United States						International						Total						United States						International						Total
Medical
Medication Delivery Solutions			$	2,661					$	1,768					$	4,429					$	2,519					$	1,774					$	4,293					$	2,483					$	1,825					$	4,308
Medication Management Solutions			2,627						670						3,297						2,303						677						2,980						1,935						598						2,533
Pharmaceutical Systems			629						1,644						2,273						666						1,563						2,229						533						1,468						2,001
Advanced Patient Monitoring			47						27						74						—						—						—						—						—						—
Total segment revenues			$	5,964					$	4,110					$	10,074					$	5,488					$	4,014					$	9,502					$	4,950					$	3,891					$	8,841
Life Sciences
Integrated Diagnostic Solutions			$	1,733					$	1,946					$	3,679					$	1,774					$	1,850					$	3,624					$	2,190					$	1,995					$	4,185
Biosciences			577						935						1,512						603						906						1,509						542						838						1,379
Total segment revenues			$	2,310					$	2,881					$	5,191					$	2,377					$	2,756					$	5,133					$	2,732					$	2,833					$	5,564
Interventional
Surgery			$	1,130					$	363					$	1,492					$	1,159					$	338					$	1,497					$	1,094					$	306					$	1,400
Peripheral Intervention			1,029						904						1,933						1,016						849						1,865						960						799						1,759
Urology and Critical Care			1,236						319						1,554						1,073						301						1,374						986						319						1,305
Total segment revenues			$	3,394					$	1,586					$	4,980					$	3,247					$	1,489					$	4,736					$	3,040					$	1,424					$	4,464
Other (a)			$	(6)					$	(62)					$	(67)					$	—					$	—					$	—					$	—					$	—					$	—
Total Company revenues from continuing operations			$	11,663					$	8,515					$	20,178					$	11,113					$	8,258					$	19,372					$	10,722					$	8,148					$	18,870

(a)    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 6.

Financial Information for Company's Segments

The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.

(Millions of dollars)			2024						2023						2022
Income from Continuing Operations Before Income Taxes
Medical (a) (b)			$	2,742					$	1,967					$	2,215
Life Sciences			1,595						1,585						1,710
Interventional			1,420						1,217						1,081
Total Segment Operating Income			5,758						4,769						5,006
Integration, restructuring and transaction expense			(458)						(313)						(173)
Net interest expense			(364)						(403)						(382)
Other unallocated items (c)			(2,931)						(2,391)						(2,668)
Total Income from Continuing Operations Before Income Taxes			$	2,005					$	1,662					$	1,783
Capital Expenditures
Medical			$	438					$	563					$	602
Life Sciences			114						139						213
Interventional			127						138						130
Corporate and All Other			46						35						28
Total Capital Expenditures			$	725					$	874					$	973
Depreciation and Amortization
Medical			$	1,216					$	1,199					$	1,144
Life Sciences			272						277						283
Interventional			786						799						789
Corporate and All Other			13						13						13
Total Depreciation and Amortization			$	2,286					$	2,288					$	2,229

(a)The amounts in 2024, 2023 and 2022 include charges of $38 million, $653 million and $72 million, respectively, recorded to Cost of products sold, to record or adjust future costs estimated for product remediation efforts.

(b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit.

(c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2024 includes a charge of $175 million to accrue an estimated liability for the SEC investigation, which is further discussed in Note 6. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2.

Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment

The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:

(Millions of dollars)			2024						2023						2022
Revenues
United States			$	11,663					$	11,113					$	10,722
EMEA			4,402						4,244						4,043
Greater Asia			2,906						2,913						3,047
Other			1,207						1,102						1,058
			$	20,178					$	19,372					$	18,870
Long-Lived Assets
United States			$	35,526					$	35,732					$	36,617
EMEA			6,706						5,317						5,126
Greater Asia			1,580						1,521						1,528
Other			2,548						1,116						1,079
Corporate			459						418						442
			$	46,818					$	44,104					$	44,792

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration